Structural Formula (Oxstructure)
Chemical structure of oxcarbazepine showing its molecular framework including rings and functional groups.*
Oxcarbazepine
Product Images NDC 63304-653
7 FDA label images from Sun Pharmaceutical Industries, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 63304-653). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
250 mL Carton Label (Carton)
Oxcarbazepine oral suspension, USP 300 mg/5 mL in a 250 mL bottle carton by Ranbaxy Pharmaceuticals, labeled for Rx only. The carton includes instructions to shake well before using and a pharmacist notice to dispense an accompanying medication guide. Storage and usage instructions are also present. Manufacturer identified as Ranbaxy Pharmaceuticals Inc., Jacksonville, FL.*
Figure 1 (Fig1)
A line graph comparing the exit rate over time on trial from Day 2 between Oxcarbazepine treatment (solid line) and Placebo (dotted line). The x-axis represents time in days from Day 2 to Day 11, and the y-axis represents the exit rate from 0 to 1. The graph includes a log-rank test p-value of 0.0001 indicating statistical analysis between groups.*
Figure 2 (Fig2)
A Kaplan-Meier survival curve chart comparing seizure rates over time from first dose to first seizure between two treatment groups: Oxcarbazepine and Placebo. The x-axis shows days from first dose, and the y-axis shows the seizure rate. The chart includes a log-rank test with a p-value of 0.046.*
Figure 3 (Fig3)
A Kaplan-Meier curve graph showing exit rate over time in days for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit (days) and the y-axis represents exit rate from 0 to 1. The LOW group has a higher exit rate earlier compared to the HIGH group. A log-rank test p-value of 0.0001 is noted, indicating statistical comparison between the groups.*
Figure 4 (Fig4)
A Kaplan-Meier survival curve chart showing exit rate over time in days for two treatment groups labeled HIGH and LOW. The y-axis represents the exit rate from 0.0 to 1.0, and the x-axis represents time to exit in days from 0 to 130. A log-rank test with a p-value of 0.0001 is indicated, demonstrating statistical comparison between the two groups.*
250 mL Bottle Label (Label)
Oxcarbazepine Oral Suspension, USP 300 mg/5 mL in a 250 mL bottle package. The label includes instructions to shake well before use and to use within 7 weeks after opening. It is labeled for pharmacist dispensing with an accompanying Medication Guide. The product is by Sun Pharmaceutical Industries, Inc., with storage instructions and safety warnings present.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
